Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 106.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 171,332 shares of the company's stock after acquiring an additional 88,224 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.11% of Xeris Biopharma worth $581,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the business. R Squared Ltd acquired a new stake in Xeris Biopharma in the 4th quarter valued at approximately $42,000. Quantbot Technologies LP purchased a new stake in shares of Xeris Biopharma in the 3rd quarter valued at $44,000. Raymond James Financial Inc. purchased a new position in Xeris Biopharma during the 4th quarter valued at about $45,000. Sunpointe LLC purchased a new stake in Xeris Biopharma during the fourth quarter worth about $71,000. Finally, Janney Montgomery Scott LLC lifted its position in shares of Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock worth $78,000 after purchasing an additional 5,500 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.
Xeris Biopharma Trading Down 2.7 %
Shares of Xeris Biopharma stock traded down $0.16 on Wednesday, hitting $5.71. The stock had a trading volume of 4,626,203 shares, compared to its average volume of 1,693,543. The company's 50 day moving average price is $3.99 and its 200 day moving average price is $3.46. The stock has a market cap of $879.00 million, a price-to-earnings ratio of -12.69 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $6.01.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on XERS shares. HC Wainwright reiterated a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum boosted their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Leerink Partners lifted their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th. Finally, Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $5.92.
Read Our Latest Report on XERS
Insider Transactions at Xeris Biopharma
In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.56% of the company's stock.
Xeris Biopharma Company Profile
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
